Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 13/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 13/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | GRN | P28799 | 1/20 | 0.36 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9883161 | 0.82 | SLC6A4 (0.48) | SLC6A2SLC6A4SLC6A3ALDH1A1LMNA | |
| SCHEMBL8277863 | 0.81 | SLC6A3 (0.48) | SLC6A2SLC6A4SLC6A3ALDH1A1LMNA | |
| SCHEMBL22664586 | 0.78 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3ALDH1A1LMNA | |
| SCHEMBL11445586 | 0.77 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3ALDH1A1LMNA | |
| SCHEMBL2632704 | 0.75 | AHR (0.44) | SLC6A2SLC6A4SLC6A3ALDH1A1LMNA | |
| SCHEMBL6571270 | 0.75 | UGT2B7 (0.49) | SLC6A2SLC6A4SLC6A3KCNH2CYP3A4 | |
| SCHEMBL11484393 | 0.74 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3ALDH1A1LMNA | |
| SCHEMBL29294802 | 0.74 | SLC6A3 (0.48) | SLC6A2SLC6A4SLC6A3ALDH1A1LMNA | |
| SCHEMBL12076553 | 0.73 | LMNA (0.38) | SLC6A2SLC6A4SLC6A3ALDH1A1LMNA | |
| SCHEMBL6950392 | 0.73 | SLC6A3 (0.46) | SLC6A2SLC6A4SLC6A3ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120135984-A1 | DUAL-ACTION INHBITORS AND METHODS OF USING SAME | AERIE PHARMACEUTICALS, INC. | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135984-A1 | DUAL-ACTION INHBITORS AND METHODS OF USING SAME | SLC6A2, ROCK2, SLC6A4 | SLC6A2 1/4885SLC6A4 3/4885SLC6A3 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.